Fengjiang Liu

Fengjiang Liu

Auto-generated profile, based on publicly available information

Fengjiang Liu

Innovative Center for Pathogen Research, Guangzhou Laboratory, Guangzhou, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2020 in Nature
Verified
Journal Article
Open access
PDF file
ZJZhenming Jin
Zhenming Jin
XDXiaoyu Du
Xiaoyu Du
YXYechun Xu
Yechun Xu
YDYongqiang Deng
Yongqiang Deng
MLMeiqin Liu
Meiqin Liu
HYHaitao Yang
Haitao Yang
A new coronavirus (CoV) identified as COVID-19 virus is the etiological agent responsible for the 2019-2020 viral pneumonia outbreak that commenced in Wuhan1–4. Currently there are no targeted therapeutics and effective treatment options remain very limited. In order to rapidly discover lead compounds for clinical use, we initiated a program of combined structure-assisted drug design, virtual drug screening and high-throughput screening to identify new drug leads that target the COVID-19 virus main protease (Mpro). Mpro is a key CoV enzyme, which plays a pivotal role in mediating viral replication and transcription, making it an attractive drug target for this virus5,6. Here, we identified a mechanism-based inhibitor, N3, by computer-aided drug design and subsequently determined the crystal structure of COVID-19 virus Mpro in complex with this compound. Next, through a combination of structure-based virtual and high-throughput screening, we assayed over 10,000 compounds including approved drugs, drug candidates in clinical trials, and other pharmacologically active compounds as inhibitors of Mpro. Six of these compounds inhibited Mpro with IC50 values ranging from 0.67 to 21.4 μM. Ebselen also exhibited promising antiviral activity in cell-based assays. Our results demonstrate the efficacy of this screening strategy, which can lead to the rapid discovery of drug leads with clinical potential in response to new infectious diseases for which no specific drugs or vaccines are available.

15 May 2020 in Science
Verified
Journal Article
Open access
PDF file
YGYan Gao
Yan Gao
LYLiming Yan
Liming Yan
YHYucen Huang
Yucen Huang
FLFengjiang Liu
Fengjiang Liu
YZYao Zhao
Yao Zhao
ZRZihe Rao
Zihe Rao
The COVID-19 RNA-synthesizing machine: Many in the scientific community have mobilized to understand the virus that is causing the global coronavirus disease 2019 (COVID-19) pandemic. Gao et al. focused on a complex that plays a key role in the replication and transcription cycle of the virus. They used cryo–electron microscopy to determine a 2.9-angstrom-resolution structure of the RNA-dependent RNA polymerase nsp12, which catalyzes the synthesis of viral RNA, in complex with two cofactors, nsp7 and nsp8. nsp12 is a target for nucleotide analog antiviral inhibitors such as remdesivir, and the structure may provide a basis for designing new antiviral therapeutics. Science , this issue p. 779

19 June 2020 in Science
Verified
Journal Article
Open access
PDF file
WDWenhao Dai
Wenhao Dai
BZBing Zhang
Bing Zhang
XJXia-Ming Jiang
Xia-Ming Jiang
HSHaixia Su
Haixia Su
JLJian Li
Jian Li
Hong LiuHong Liu
Hong Liu
Promising antiviral protease inhibitors: With no vaccine or proven effective drug against the virus that causes coronavirus disease 2019 (COVID-19), scientists are racing to find clinical antiviral treatments. A promising drug target is the viral main protease M pro , which plays a key role in viral replication and transcription. Dai et al. designed two inhibitors, 11a and 11b, based on analyzing the structure of the M pro active site. Both strongly inhibited the activity of M pro and showed good antiviral activity in cell culture. Compound 11a had better pharmacokinetic properties and low toxicity when tested in mice and dogs, suggesting that this compound is a promising drug candidate. Science , this issue p. 1331

1 July 2020 in Cell
Verified
Journal Article
Closed access
QWQuan Wang
Quan Wang
JWJiqin Wu
Jiqin Wu
HWHaofeng Wang
Haofeng Wang
YGYan Gao
Yan Gao
QLQiaojie Liu
Qiaojie Liu
ZRZihe Rao
Zihe Rao

26 May 2023 in Molecular Cell
Verified
Journal Article
Closed access
YLYuezheng Lai
Yuezheng Lai
YZYuying Zhang
Yuying Zhang
SZShan Zhou
Shan Zhou
JXJinxu Xu
Jinxu Xu
ZDZhanqiang Du
Zhanqiang Du
HGHongri Gong
Hongri Gong

3 March 2022 in Molecular Metabolism
Verified
Journal Article
Open access
BJBin Jiang
Bin Jiang
DWDongdong Wang
Dongdong Wang
YHYunfu Hu
Yunfu Hu
WLWenxuan Li
Wenxuan Li
FLFengjiang Liu
Fengjiang Liu
QCQi Chen
Qi Chen
Chronic inflammatory response plays a prominent role in obesity-related nonalcoholic fatty liver disease (NAFLD). However, the intrahepatic triggering mechanism of inflammation remains obscure. This study aimed to elucidate the role of serum amyloid A1 (SAA1), an acute-phase response protein, in the obesity-induced hepatic inflammation and NAFLD. Male mice were fed a high fat diet (HFD) for 16 weeks, and insulin resistance, hepatic steatosis, and inflammation in mice were monitored. Murine SAA1/2 was genetically manipulated to investigate the role of SAA1 in NAFLD. We found that SAA1 was increased in the NAFLD liver in both humans and mice. Knockout of SAA1/2 or knockdown of hepatic SAA1/2 promoted energy expenditure and alleviated HFD-induced metabolic disorder, hepatic steatosis, and inflammation. Endogenous overexpression of SAA1 in hepatocytes by adeno-associated virus 8 (AAV8) transfection aggravated overnutrition-associated gain of body weight, insulin resistance, hepatic lipid accumulation, and liver injury, which were markedly alleviated by knockout of murine toll-like receptor 4 (TLR4). Mechanistically, SAA1 directly bound with TLR4/myeloid differentiation 2 (MD2) to induce TLR4 internalization, leading to the activation of nuclear factor (NF)-κB signaling and production of both SAA1 and other inflammatory cytokines, including interleukin (IL)-6 and C–C chemokine ligand (CCL2) in hepatocytes. Administration of HFD mice with an AAV8-shRNA-SAA1/2 showed a therapeutic effect on hepatic inflammation and NAFLD progression. These results demonstrate that SAA1 triggers hepatic steatosis and intrahepatic inflammatory response by forming a SAA1/TLR4/NF-κB/SAA1 feedforward regulatory circuit, which, in turn, leads to NAFLD progression. SAA1 may act as a potential target for the disease intervention.